Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations.

作者信息

Fleming Thomas R, Emerson Scott S

机构信息

Department of Biostatistics, University of Washington, Seattle, USA.

出版信息

N Engl J Med. 2011 Oct 27;365(17):1557-9. doi: 10.1056/NEJMp1110639. Epub 2011 Oct 5.

DOI:10.1056/NEJMp1110639

PMID:21992495

Abstract

摘要

相似文献

Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations.

N Engl J Med. 2011 Oct 27;365(17):1557-9. doi: 10.1056/NEJMp1110639. Epub 2011 Oct 5.

FDA advisory decision highlights some problems inherent in pragmatic trials.

JAMA. 2011 Nov 2;306(17):1851-2. doi: 10.1001/jama.2011.1570.

New alternative to warfarin may help reduce stroke risk in patients with AF.

JAMA. 2011 Jan 5;305(1):25-6. doi: 10.1001/jama.2010.1894.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

N Engl J Med. 2011 Dec 15;365(24):2333; author reply 2335. doi: 10.1056/NEJMc1112233.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

N Engl J Med. 2011 Dec 15;365(24):2333-4; author reply 2335. doi: 10.1056/NEJMc1112233.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

N Engl J Med. 2011 Dec 15;365(24):2334; author reply 2335. doi: 10.1056/NEJMc1112233.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

N Engl J Med. 2011 Dec 15;365(24):2334-5; author reply 2335. doi: 10.1056/NEJMc1112233.

New agents to prevent strokes in nonvalvular atrial fibrillation.

Methodist Debakey Cardiovasc J. 2012 Jul-Sep;8(3):44-6. doi: 10.14797/mdcj-8-3-44.

Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.

Cardiovasc J Afr. 2012 Oct;23(9):525-6.

[Differential therapy with the new anticoagulants, 5].

MMW Fortschr Med. 2013 May 16;155(9):20. doi: 10.1007/s15006-013-0676-8.

引用本文的文献

Stroke Prevention in Atrial Fibrillation: Focus on Latin America.

Arq Bras Cardiol. 2016 Dec;107(6):576-589. doi: 10.5935/abc.20160116. Epub 2016 Aug 11.

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.

Core Evid. 2015 May 28;10:63-73. doi: 10.2147/CE.S61441. eCollection 2015.

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Stroke. 2014 Dec;45(12):3754-832. doi: 10.1161/STR.0000000000000046. Epub 2014 Oct 28.

On robustness of noninferiority clinical trial designs against bias, variability, and nonconstancy.

J Biopharm Stat. 2015;25(1):206-25. doi: 10.1080/10543406.2014.923738.

Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation.

J Stroke. 2013 Sep;15(3):144-52. doi: 10.5853/jos.2013.15.3.144. Epub 2013 Sep 27.

A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.

Clin Drug Investig. 2013 Nov;33(11):847-53. doi: 10.1007/s40261-013-0134-5.

Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Drugs. 2013 May;73(7):715-39. doi: 10.1007/s40265-013-0056-9.

A systems approach to designing effective clinical trials using simulations.

Circulation. 2013 Jan 29;127(4):517-26. doi: 10.1161/CIRCULATIONAHA.112.123034. Epub 2012 Dec 21.

Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database.

BMJ Open. 2012 Dec 14;2(6). doi: 10.1136/bmjopen-2012-001768. Print 2012.

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.

Neurology. 2012 Oct 2;79(14):1428-34. doi: 10.1212/WNL.0b013e31826d5fe8. Epub 2012 Sep 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr
超能文献

Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr超能文献

Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr
超能文献